{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:20:30Z","timestamp":1783178430714,"version":"3.54.6"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100024253","name":"Western Australian Future Health and Innovation Fund, Government of Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100025520","name":"Medical Research Future Fund","doi-asserted-by":"crossref","award":["2023559"],"award-info":[{"award-number":["2023559"]}],"id":[{"id":"10.13039\/501100025520","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100020265","name":"Stan Perron Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001801","name":"University of Western Australia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001801","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40290-026-00614-0","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:42:13Z","timestamp":1780569733000},"page":"265-273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regulating the Irregular: Phage Therapy and the Case for a Regulatory Sandbox Approach in Australia"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0445-9655","authenticated-orcid":false,"given":"Marco","family":"Rizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Stick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Kicic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya V.","family":"Karpievitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"2","key":"614_CR1","doi-asserted-by":"publisher","first-page":"e00066","DOI":"10.1128\/CMR.00066-18","volume":"32","author":"FL Gordillo Altamirano","year":"2019","unstructured":"Gordillo Altamirano FL, Barr JJ. Phage therapy in the postantibiotic era. Clin Microbiol Rev. 2019;32(2):e00066-e118.","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"614_CR2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI187996","volume":"135","author":"MK Kim","year":"2025","unstructured":"Kim MK, Suh GA, Culle GD, et al. Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches. J Clin Invest. 2025;135(5):e187996.","journal-title":"J Clin Invest"},{"issue":"8","key":"614_CR3","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S1473-3099(21)00612-5","volume":"22","author":"S Uyttebroek","year":"2022","unstructured":"Uyttebroek S, Chen B, Onsea J, et al. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infect Dis. 2022;22(8):e208\u201320.","journal-title":"Lancet Infect Dis"},{"key":"614_CR4","unstructured":"ACSQHC. AURA 2023: fifth Australian report on antimicrobial use and resistance in human health. 2023, Australian Commission on Safety and Quality in Health Care: Sydney. Available from: https:\/\/www.amr.gov.au\/resources\/aura-2023-fifth-australian-report-antimicrobial-use-and-resistance-human-health. [Accessed 11 May 2026]."},{"issue":"10325","key":"614_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"C Murray","year":"2022","unstructured":"Murray C, Ikuta K, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629\u201355.","journal-title":"Lancet"},{"key":"614_CR6","unstructured":"O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. Review on antimicrobial resistance, 2016. Available from: https:\/\/apo.org.au\/node\/63983. [Accessed 11 May 2026]."},{"issue":"3","key":"614_CR7","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1128\/AAC.45.3.649-659.2001","volume":"45","author":"A Sulakvelidze","year":"2001","unstructured":"Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob Agents Chemother. 2001;45(3):649\u201359.","journal-title":"Antimicrob Agents Chemother"},{"key":"614_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0065-2164(10)70007-1","volume":"70","author":"P Hyman","year":"2010","unstructured":"Hyman P, Abedon ST. Bacteriophage host range and bacterial resistance. Adv Appl Microbiol. 2010;70:217\u201348.","journal-title":"Adv Appl Microbiol"},{"key":"614_CR9","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.3389\/fmicb.2016.01352","volume":"7","author":"A Ross","year":"2016","unstructured":"Ross A, Ward S, Hyman P. More is better: selecting for broad host range bacteriophages. Front Microbiol. 2016;7:1352.","journal-title":"Front Microbiol"},{"issue":"5","key":"614_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103526","volume":"28","author":"I Heikkinen","year":"2023","unstructured":"Heikkinen I, Escola S, Acha V, et al. Role of innovation in pharmaceutical regulation: a proposal for principles to evaluate EU General Pharmaceutical Legislation from the innovator perspective. Drug Discov Today. 2023;28(5):103526.","journal-title":"Drug Discov Today"},{"key":"614_CR11","volume-title":"The interplay of global standards and EU Pharmaceutical Regulation","author":"S R\u00f6ttger-Wirtz","year":"2023","unstructured":"R\u00f6ttger-Wirtz S. The interplay of global standards and EU Pharmaceutical Regulation. 1st ed. Bloomsbury: Hart Studies in Law and Health; 2023.","edition":"1st ed"},{"issue":"1","key":"614_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s44259-025-00087-2","volume":"3","author":"SM Hickson","year":"2025","unstructured":"Hickson SM, Ledger EL, Wells TJ. Emerging antimicrobial therapies for Gram-negative infections in human clinical use. NPJ Antimicrob Resist. 2025;3(1):16.","journal-title":"NPJ Antimicrob Resist."},{"issue":"12","key":"614_CR13","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1016\/j.apsb.2022.05.007","volume":"12","author":"H Ling","year":"2022","unstructured":"Ling H, Lou X, Luo Q, et al. Recent advances in bacteriophage-based therapeutics: insight into the post-antibiotic era. Acta Pharm Sin B. 2022;12(12):4348\u201364.","journal-title":"Acta Pharm Sin B."},{"issue":"1","key":"614_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s12250-014-3557-0","volume":"30","author":"M Kutateladze","year":"2015","unstructured":"Kutateladze M. Experience of the Eliava Institute in bacteriophage therapy. Virol Sin. 2015;30(1):80\u20131.","journal-title":"Virol Sin"},{"issue":"6","key":"614_CR15","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.cmi.2023.01.011","volume":"29","author":"WJ Metsemakers","year":"2023","unstructured":"Metsemakers WJ, Onsea J, Moriarty TF, et al. Bacteriophage therapy for human musculoskeletal and skin\/soft tissue infections. Clin Microbiol Infect. 2023;29(6):695\u2013701.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"614_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/v10020064","volume":"10","author":"J-P Pirnay","year":"2018","unstructured":"Pirnay J-P, Verbeken G, Ceyssens P-J, et al. The magistral phage. Viruses. 2018;10(2):64.","journal-title":"Viruses"},{"key":"614_CR17","unstructured":"MHRA, editor. Regulatory considerations for therapeutic use of bacteriophages in the UK. 2025. Available from: https:\/\/www.gov.uk\/government\/publications\/regulatory-considerations-for-therapeutic-use-of-bacteriophages-in-the-uk. [Accessed 11 May 2026]."},{"key":"614_CR18","unstructured":"US FDA, editor. Science and regulation of bacteriophage therapy. 2021. Available from: https:\/\/www.fda.gov\/news-events\/fda-meetings-conferences-and-workshops\/science-and-regulation-bacteriophage-therapy-workshop-08302021. [Accessed 11 May 2026]."},{"key":"614_CR19","unstructured":"Bacteriophage therapy in spinal cord injury patients with bacteriuria. 2025, clinical trial. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06559618. [Accessed 11 May 2026]."},{"key":"614_CR20","unstructured":"Phage therapy for recurrent UTIs in kidney transplant recipients. 2025, clinical trial. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06409819. [Accessed 11 May 2026]."},{"key":"614_CR21","unstructured":"A study of LBP-EC01 in the treatment of acute uncomplicated UTI caused by drug resistant E. Coli (ELIMINATE). 2022, clinical trial. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05488340. [Accessed 11 May 2026]."},{"key":"614_CR22","unstructured":"Health and biosciences: targeted regulatory review: program and policy and initiatives and novel regulatory approaches. 2021. Available from: https:\/\/www.canada.ca\/en\/health-canada\/corporate\/about-health-canada\/legislation-guidelines\/acts-regulations\/targeted-regulatory-reviews\/health-biosciences-sector-regulatory-review.html. [Accessed 11 May 2026]."},{"key":"614_CR23","unstructured":"Cytophage Technologies Ltd. secures Government of Canada new substance notification approval to facilitate Enterococcus phage therapy trials. 2025. Available from: https:\/\/www.thenewswire.com\/press-releases\/1LYzFbDMq-cytophage-technologies-ltd-secures-government-of-canada-new-substance-notification-approval-to-facilitate-enterococcus-phage-therapy-trials.html. [Accessed 11 May 2026]."},{"issue":"2","key":"614_CR24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.intonc.2025.03.001","volume":"1","author":"Y Qiu","year":"2025","unstructured":"Qiu Y, Yao H, Ren P, et al. Regulatory sandbox expansion: exploring the leap from fintech to medical artificial intelligence. Intell Oncol. 2025;1(2):120\u20137.","journal-title":"Intell Oncol"},{"issue":"1","key":"614_CR25","first-page":"107","volume":"16","author":"S Ranchordas","year":"2024","unstructured":"Ranchordas S, Vinci V. Regulatory sandboxes and innovation-friendly regulation: between collaboration and capture. Ital J Public Law. 2024;16(1):107\u201339.","journal-title":"Ital J Public Law"},{"issue":"1","key":"614_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/rof\/rfad017","volume":"28","author":"G Cornelli","year":"2024","unstructured":"Cornelli G, Doerr S, Gambacorta L, et al. Regulatory sandboxes and Fintech funding: evidence from the UK. Rev Finance. 2024;28(1):203\u201333.","journal-title":"Rev Finance."},{"issue":"3","key":"614_CR27","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1017\/err.2025.10","volume":"16","author":"A Molitorisov\u00e1","year":"2025","unstructured":"Molitorisov\u00e1 A, Purnhagen K. Regulatory sandboxes for novel foods. Eur J Risk Regul. 2025;16(3):1063\u201381.","journal-title":"Eur J Risk Regul"},{"key":"614_CR28","unstructured":"ABF. Regulatory sandbox. 2025. Available from: https:\/\/www.abf.gov.au\/about-us\/what-we-do\/regulatory-sandbox. [Accessed 11 May 2026]."},{"issue":"6","key":"614_CR29","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s40258-021-00665-1","volume":"19","author":"E Leckenby","year":"2021","unstructured":"Leckenby E, Dawoud D, Bouvy J, et al. The sandbox approach and its potential for use in health technology assessment: a literature review. Appl Health Econ Health Policy. 2021;19(6):857\u201369.","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"614_CR30","first-page":"19","volume":"38","author":"M Guerriaud","year":"2024","unstructured":"Guerriaud M. \u201cRegulatory sandboxes\u201d could solve the regulatory problems encountered in Europe and arising from innovation in biological medicinal products. Pharmaceut Med. 2024;38(1):19\u201323.","journal-title":"Pharmaceut Med"},{"issue":"1","key":"614_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-65584-4","volume":"16","author":"E Chiti","year":"2025","unstructured":"Chiti E, Micera S, Palmerini E. Making the case for sandboxes in implantable neurotechnologies. Nat Commun. 2025;16(1):9783.","journal-title":"Nat Commun"},{"key":"614_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.rare.2025.100110","volume":"3","author":"G Zanello","year":"2025","unstructured":"Zanello G, Stoyanova-Beninska V, Iliach O, et al. Regulatory sandboxes: a new frontier for rare disease therapies. Rare. 2025;3:100110.","journal-title":"Rare"},{"issue":"8","key":"614_CR33","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nrd.2018.34","volume":"17","author":"S Khozin","year":"2018","unstructured":"Khozin S, Pazdur R, Shah A. INFORMED: an incubator at the US FDA for driving innovations in data science and agile technology. Nat Rev Drug Discov. 2018;17(8):529\u201330.","journal-title":"Nat Rev Drug Discov"},{"key":"614_CR34","doi-asserted-by":"publisher","unstructured":"Ranchordas S, Van Klink B. Experimental regulations and regulatory sandboxes: law without order? Law and Method. 2021. Available from: https:\/\/doi.org\/10.5553\/REM\/.000064. [Accessed 29 May 2026].","DOI":"10.5553\/REM\/.000064"},{"key":"614_CR35","doi-asserted-by":"publisher","DOI":"10.1017\/9781009379007","volume-title":"An introduction to law and regulation","author":"K Yeung","year":"2024","unstructured":"Yeung K, Ranchord\u00e1s S. An introduction to law and regulation. 2nd ed. Cambridge: Cambridge University Press; 2024.","edition":"2nd ed"},{"issue":"3","key":"614_CR36","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1017\/err.2020.8","volume":"11","author":"W-G Ringe","year":"2020","unstructured":"Ringe W-G, Ruof C. Regulating Fintech in the EU: the case for a guided sandbox. Eur J Risk Regul. 2020;11(3):604\u201329.","journal-title":"Eur J Risk Regul"},{"key":"614_CR37","doi-asserted-by":"publisher","DOI":"10.4324\/9781003293811","volume-title":"The regulation of medical products: dope, drugs and devices","author":"P Gleeson","year":"2024","unstructured":"Gleeson P. The regulation of medical products: dope, drugs and devices. 1st ed. Routledge; London 2024.","edition":"1"},{"key":"614_CR38","unstructured":"EMA. Reform of the EU pharmaceutical legislation. 2023. Available from: https:\/\/health.ec.europa.eu\/medicinal-products\/reform-eu-pharmaceutical-legislation_en. [Accessed 11 May 2026]."},{"key":"614_CR39","unstructured":"TGA. Good manufacturing practice: an overview. 2017. Available from: https:\/\/www.tga.gov.au\/how-we-regulate\/manufacturing\/good-manufacturing-practice-overview. [Accessed 11 May 2026]."},{"key":"614_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2023.123867","volume":"1229","author":"R Roshankhah","year":"2023","unstructured":"Roshankhah R, Jackson K, Nguyen TTN, et al. Purification of phage for therapeutic applications using high throughput anion exchange membrane chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2023;1229:123867.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"614_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/978-1-4939-7343-9_5","volume":"1681","author":"D Vandenheuvel","year":"2018","unstructured":"Vandenheuvel D, Rombouts S, Adriaenssens EM. Purification of bacteriophages using anion-exchange chromatography. Methods Mol Biol. 2018;1681:59\u201369.","journal-title":"Methods Mol Biol"},{"key":"614_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.01161","volume":"11","author":"L Bretaudeau","year":"2020","unstructured":"Bretaudeau L, Tremblais K, Aubrit F, et al. Good manufacturing practice (GMP) compliance for phage therapy medicinal products. Front Microbiol. 2020;11:1161.","journal-title":"Front Microbiol"},{"issue":"1","key":"614_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-024-08100-1","volume":"25","author":"O Hawksworth","year":"2024","unstructured":"Hawksworth O, Chatters L, Julious S, et al. A methodological review of randomised n-of-1 trials. Trials. 2024;25(1):263.","journal-title":"Trials"},{"issue":"1","key":"614_CR44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41573-024-01059-3","volume":"24","author":"AH Jonker","year":"2025","unstructured":"Jonker AH, Tataru EA, Graessner H, et al. The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap. Nat Rev Drug Discov. 2025;24(1):40\u201356.","journal-title":"Nat Rev Drug Discov"},{"key":"614_CR45","unstructured":"WHO. Influenza. Available from: https:\/\/www.who.int\/teams\/health-product-policy-and-standards\/standards-and-specifications\/norms-and-standards\/vaccine-standardization\/influenza. [Accessed 11 May 2026]."},{"issue":"19","key":"614_CR46","first-page":"185","volume":"97","author":"WHO","year":"2022","unstructured":"WHO. Vaccines against influenza: WHO position paper 2022. Wkly Epidemiol Rec. 2022;97(19):185\u2013208.","journal-title":"Wkly Epidemiol Rec"},{"issue":"10","key":"614_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11101573","volume":"11","author":"X He","year":"2023","unstructured":"He X, Zhang T, Huan S, et al. Novel influenza vaccines: from research and development (R&D) challenges to regulatory responses. Vaccines. 2023;11(10):1573.","journal-title":"Vaccines"},{"issue":"23","key":"614_CR48","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1056\/NEJMsb2512695","volume":"393","author":"V Prasad","year":"2025","unstructured":"Prasad V, Makary MA. FDA\u2019s new plausible mechanism pathway. N Engl J Med. 2025;393(23):2365\u20137.","journal-title":"N Engl J Med"},{"key":"614_CR49","unstructured":"MHRA. Rare therapies and UK regulatory considerations. 2025. Available from: https:\/\/www.gov.uk\/government\/publications\/rare-therapies-and-uk-regulatory-considerations. [Accessed 11 May 2026]."},{"issue":"1","key":"614_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s42522-024-00111-x","volume":"6","author":"HL Brown","year":"2024","unstructured":"Brown HL, Pursley IG, Horton DL, et al. One health: a structured review and commentary on trends and themes. One Health Outlook. 2024;6(1):17.","journal-title":"One Health Outlook."},{"issue":"3","key":"614_CR51","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/rego.12487","volume":"17","author":"WG Johnson","year":"2022","unstructured":"Johnson WG. Caught in quicksand? Compliance and legitimacy challenges in using regulatory sandboxes to manage emerging technologies. Regul Governance. 2022;17(3):709\u201325.","journal-title":"Regul Governance"},{"issue":"12","key":"614_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-065401","volume":"12","author":"A Khatami","year":"2022","unstructured":"Khatami A, Foley DA, Warner MS, et al. Standardised treatment and monitoring protocol to assess safety and tolerability of bacteriophage therapy for adult and paediatric patients (STAMP study): protocol for an open-label, single-arm trial. BMJ Open. 2022;12(12):e065401.","journal-title":"BMJ Open"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00614-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-026-00614-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00614-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:04:37Z","timestamp":1783177477000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-026-00614-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["614"],"URL":"https:\/\/doi.org\/10.1007\/s40290-026-00614-0","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"19 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: the funding note and the author David G. Hancock affiliations have been updated.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by a Western Australian Future Health Research and Innovation Challenge Grant, the Conquer CF Foundation, Cystic Fibrosis WA (CFWA), the Medical Research Future Fund (2023559) and the Stan Perron Charitable Foundation. Marco Rizzi is a Co-Director of the UWA Centre for Health Law and Policy. Yuliya V. Karpievitch is a CFWA Fellow and is supported through contributions from Allegra Capital. Stephen M. Stick is a National Health and Medical Research Council Practitioner Fellow holding a National Health and Medical Research Council Investigator Grant (2007725), and Anthony Kicic is a Rothwell Family Fellow.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yuliya V. Karpievitch and Stephen M. Stick are Board Members of OpenPhage (\n                      \n                      ). Marco Rizzi, David G. Hancock and Anthony Kicic have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MR and YVK conceptualised and drafted the initial manuscript and contributed equally. All authors reviewed and revised the manuscript and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}